Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea International Journal of Hematology, 05/24/2012

Kim D et al. – Treatment adherence in the early treatment period was one of the important independent predictors of favorable long–term outcome. Durable cytogenetic and molecular responses were maintained in a majority of patients treated with optimal dose intensity.

Read this article on International Journal of Hematology

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Physician Assistant Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?